Salah Hadi

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Meike H. van der Ree, J. Marleen de Vree, F. Stelma et al. · The Lancet · 2017 · 268 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placebo‐controlled</scp>, <scp>double‐blind</scp> phase I/Ib studies in healthy subjects and patients

Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld et al. · Clinical and Translational Science · 2022 · 102 citations · Full text

Medicine, Neurology, Pharmacology +17

Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus

Armel Stockis, Jan Hartstra, Muriel Mollet et al. · Epilepsia · 2016 · 28 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Results and evaluation of a first‐in‐human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods

Stefan Sturm, Marie‐Laure Delporte, Salah Hadi et al. · British Journal of Clinical Pharmacology · 2017 · 14 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17